← All trials
NCT04475302
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2020
- Primary completion
- Jan 31, 2021
- Completion date
- May 31, 2021
- First posted
- Jul 17, 2020
- Last posted
- Jul 23, 2020
- Enrollment
- 2175
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute for Research in Tuberculosis, Chennai, IndiaLead sponsor
- King Edward Memorial Hospital, MumbaiCollaborator
- All India Institute of Medical SciencesOverall official - principal investigator
- All India Institute of Medical SciencesCollaborator
- Government of IndiaOverall official - principal investigator
- Government of IndiaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.